Literature DB >> 18428668

Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.

M Angela Cenci1, Martin Lundblad.   

Abstract

This unit provides detailed protocols for establishing rodent models of L-DOPA-induced dyskinesia. The 6-hydroxydopamine (6-OHDA) lesion procedure is described in more detail for mice than for rats since the lesioning procedure in rats has been described extensively in previous work and is less difficult to perform. Unlike primate models, rodent models of L-DOPA-induced dyskinesia are relatively simple and fast to set up, thus being affordable to most laboratories. These models allow for studying the dyskinetic complications of L-DOPA treatment on large groups of animals under strictly controlled experimental conditions. Along with information and structured protocols for the practical execution of the test, this unit provides a detailed description of the rating scale and the phenomenology of rodent abnormal involuntary movements, and suggestions for beginners. Copyright 2007 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18428668     DOI: 10.1002/0471142301.ns0925s41

Source DB:  PubMed          Journal:  Curr Protoc Neurosci        ISSN: 1934-8576


  85 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2010-08-23       Impact factor: 4.436

Review 3.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

4.  Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.

Authors:  Roberta Marongiu; Margarita Arango-Lievano; Veronica Francardo; Peter Morgenstern; Xiaoqun Zhang; M Angela Cenci; Per Svenningsson; Paul Greengard; Michael G Kaplitt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

5.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

6.  Anatomical and electrophysiological changes in striatal TH interneurons after loss of the nigrostriatal dopaminergic pathway.

Authors:  Bengi Ünal; Fulva Shah; Janish Kothari; James M Tepper
Journal:  Brain Struct Funct       Date:  2013-10-31       Impact factor: 3.270

7.  Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

Authors:  Maryka Quik; Carla Campos; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

8.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

9.  A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.

Authors:  Allison E Girasole; Matthew Y Lum; Diane Nathaniel; Chloe J Bair-Marshall; Casey J Guenthner; Liqun Luo; Anatol C Kreitzer; Alexandra B Nelson
Journal:  Neuron       Date:  2018-02-01       Impact factor: 17.173

10.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.